Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA

Robinson, Harriet L.; Hunt, Lawrence A.; Webster, Robert G.

doi:10.1016/0264-410x(93)90385-b

Cited by 397 publications

(155 citation statements)

References 15 publications

Supporting

Mentioning

148

Contrasting

Order By: Relevance

“…These results are significant in that they confirm initial observations on the immunogenicity of DNA vaccines in animal models [37,[48][49][50]. The DNA prime-protein boost approach will not only accelerate the testing of more candidate HIV vaccines that aim to achieve improved neutralizing antibody responses, but will also provide a new platform for the development of future vaccines against a wide range of existing or emerging pathogens.…”

Section: Discussionsupporting

confidence: 71%

Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime–protein boost HIV-1 vaccine in healthy human volunteers

Wang

Kennedy

West

et al. 2008

Vaccine

124

View full text Add to dashboard Cite

An optimally effective AIDS vaccine would likely require the induction of both neutralizing antibody and cell-mediated immune responses, which has proven difficult to obtain in previous clinical trials. Here we report the induction of Human Immunodeficiency Virus Type-1 (HIV-1)-specific immune responses in healthy adult volunteers that received the multi-gene, polyvalent, DNA prime-protein boost HIV-1 vaccine formulation, DP6−001 in a Phase I clinical trial conducted in healthy adult volunteers of both genders. Robust cross-subtype HIV-1-specific T cell responses were detected in IFNγ ELISPOT assays. Furthermore, we detected high titer serum antibody responses that recognized a wide range of primary HIV-1 Env antigens and also neutralized pseudotyped viruses that express the primary Env antigens from multiple HIV-1 subtypes. These findings demonstrate that the DNA prime-protein boost approach is an effective immunization method to elicit both humoral and cellmediated immune responses in humans, and that a polyvalent Env formulation could generate broad immune responses against HIV-1 viruses with diverse genetic backgrounds.

show abstract

Section: Discussionsupporting

confidence: 71%

Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime–protein boost HIV-1 vaccine in healthy human volunteers

Wang

Kennedy

West

et al. 2008

Vaccine

124

View full text Add to dashboard Cite

show abstract

“…Following these results, many studies were undertaken which demonstrated that naked pDNA can be used for vaccination. 2,3 mRNA was rarely exploited until the late nineties when Gilboa's group showed that adoptive transfer of mRNAtransfected dendritic cells (DCs) primes a T-cell immune response. 4 But, the direct injection of naked mRNA for vaccination or gene complementation remained quite unexplored, being reported in only four articles from three different teams [5][6][7][8] (for a review on mRNA-based vaccines, see Pascolo 9 ).…”

mentioning

confidence: 99%

Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent

et al. 2007

View full text Add to dashboard Cite

The development of new treatments in the post-genomic era requires methods for safe delivery of foreign genetic information in vivo. As a transient, natural and controllable alternative to recombinant viruses or plasmid DNA (pDNA), purified or in vitro transcribed messenger RNA (mRNA) can be used for the expression of any therapeutic protein in vitro and in vivo. As it has been shown previously, the simple injection of naked mRNA results in local uptake and expression. We show here that this process, in the skin, can greatly be modulated according to the injection solution composition and blocked by an excess of competing nucleic acids or a drug affecting cytosolic mobility. Different cell types at the site of injection can take up the foreign nucleic acid molecules and the protein translated from this is detected for no more than a few days. To test this gene transfer method in humans, we produced in vitro transcribed mRNA under good manufacturing practice (GMP) conditions in a dedicated facility. After injection into the human dermis, we could document the translation of the exogenous mRNA. Our results pave the way toward the use of mRNA as a vehicle for transient gene delivery in humans.

show abstract

“…DNA vaccination against various pathogens, including human immunodeficiency virus (HIV) [15,16], bovine herpes virus [17], influenza [18][19][20], rabies virus [21], hepatitis B virus [22] and malaria [23] have been evaluated as vaccines in several animal models. Vaccination of mice via intranasal and intramuscular routes with plasmid DNA expressing HSV-1 gB induced protection against HSV-1 challenge through a vaginal route of infection [24].…”

Section: Introductionmentioning

confidence: 99%

Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based immunisation with herpes simplex virus type-1 genes specifying glycoproteins gB and gD

Baghian¹,

Chouljenko²,

D’Auvergne

et al. 2002

Journal of Medical Microbiology

View full text Add to dashboard Cite

and {Vaxcel, Norcross, GA, USA DNA-based vaccines were employed to assess protective immunity against herpes simplex virus in experimental infections of hairless (strain SKH1) and BALB/c mice. Mice were vaccinated with plasmids containing the herpes simplex virus type-1 (HSV-1) glycoprotein B (gB) or D (gD) genes under the human cytomegalovirus immediate-early promoter control. Vaccines were injected intramuscularly (i.m.) or intraperitoneally (i.p.) as purified DNA alone or as formulations supplemented with different non-ionic block copolymers. Antibody responses were assessed by immunofluorescence and radioimmunoprecipitation assays. Mice inoculated with either gB or gD plasmid, alone or with non-ionic block copolymers CRL 1029 and CRL 1190, produced high levels of antibodies specific for gB or gD. Three weeks after the last vaccination, mice were challenged with a clinical HSV-1 isolate (ABGK-1) by inoculation of a shaved and subsequently scarified area between the third and fourth lumbar vertebrae. Mice immunised with either gD or gB plasmid alone or mixed with copolymers were protected against lethal HSV-1 challenge when immunisation was performed via the i.m. route. Immunisations given via the i.p. route induced humoral responses in some mice and protected the animals against lethal HSV-1 challenge only when the formulations contained copolymers. The BALB/c mouse model was shown to be as good a model as the hairless mouse model.

show abstract

Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA

Cited by 397 publications

References 15 publications

Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime–protein boost HIV-1 vaccine in healthy human volunteers

Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime–protein boost HIV-1 vaccine in healthy human volunteers

Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent

Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based immunisation with herpes simplex virus type-1 genes specifying glycoproteins gB and gD

Contact Info

Product

Resources

About